PSA (prostate specific antigen) screening has increased PCa diagnosis and decreased PCa mortality overall, but low levels of PSA are not predictive of tumor aggressiveness and there is controversy over using PSA to detect indolent PCa [2, 3]. The gene discussed is KLK3; the disease is neoplasm.